<DOC>
	<DOCNO>NCT02098187</DOCNO>
	<brief_summary>The purpose early feasibility study investigate pharmacokinetics MP-3180 administer rise dos evaluate use Optical Renal Function Monitor ( ORFM ) , investigational noninvasive fluorescence detection device .</brief_summary>
	<brief_title>Pharmacokinetics MP-3180 Use Noninvasive Fluorescence Detection Device Healthy Volunteers</brief_title>
	<detailed_description>This open-label , rise single-dose study investigate pharmacokinetics investigational agent , MP-3180 , evaluate use Optical Renal Function Monitor ( ORFM ) , investigational noninvasive fluorescence detection device . Single-dose pharmacokinetics four dose level evaluate follow administration single , intravenous dose MP-3180 . Iohexol also administer followed saline . Prior administration MP-3180 iohexol , ORFM sensor probe affix four location body participant . The noninvasive fluorescent signal MP-3180 measure use ORFM investigational device continuously approximately four hour post MP-3180 administration . For determination pharmacokinetic disposition MP-3180 iohexol , blood sample collect participant provide individual complete blood collection study . The pharmacokinetics MP-3180 iohexol assess statistical comparison pharmacokinetic parameter derive plasma concentration-time curve urine recovery data .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>1 . Age : 22 year age old 2 . Sex : Males childbearing potential female 3 . Capable informed consent 4 . Weight restriction : 1. least 50 kg ( 110 lb ) men 2. least 48 kg ( 106 lb ) woman 3. participant Body Mass Index ( BMI ) less equal 33 great equal 19 5 . All participant judge Principal Investigator Medical SubInvestigator physician normal healthy prestudy medical evaluation perform within 28 day initial dose study medication 1 . Institutionalized participant use 2 . History significant cardiovascular disease , renal , pulmonary , hematologic , endocrine , immunologic , dermatologic , neurologic ( include history seizure disorder ) , psychological , musculoskeletal disease malignancy unless deem clinically significant Principal Investigator Medical SubInvestigator . 3 . Donation loss blood plasma : 50 mL 499 mL within 30 day prior initial dose study medication ; 499 mL within 56 day prior initial dose study medication . 4 . Intolerance venipuncture . 5 . Participants receive investigational drug within 30 day prior initial dose study medication . 6 . History drug and/or alcohol abuse within past year , unless currently enrol abstinence program . 7 . History allergy hypersensitivity MP3180 iohexol , related product , inactive ingredient . 8 . History skin sensitivity adhesive ( e.g . BandAids , surgical tape ) . 9 . Any food allergy , intolerance , restriction special diet , opinion Principal Investigator Medical SubInvestigator , could contraindicate participant 's participation study . 10 . History allergy hypersensitivity iodine contain contrast medium drug . 11 . Acute illness time either prestudy medical evaluation dosing . 12 . Social Habits : 1 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 2 . Ingestion vitamins herbal supplement within 7 day prior initial dose study medication . 3 . Any significant change dietary exercise habit within 48 hour prior initial dose study medication . 13 . Medications : . Use prescription overthecounter ( OTC ) medication within 7 day prior initial dose study medication . 14 . Not within normal limit clinically significant lab testing ; serum chemistry , hematology , urinalysis .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Acute Kidney Injury</keyword>
</DOC>